These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36700868)

  • 1. Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020.
    Adlhoch C; Delgado-Sanz C; Carnahan A; Larrauri A; Popovici O; Bossuyt N; Thomas I; Kynčl J; Slezak P; Brytting M; Guiomar R; Redlberger-Fritz M; Maistre Melillo J; Melillo T; van Gageldonk-Lafeber AB; Marbus SD; O'Donnell J; Domegan L; Gomes Dias J; Olsen SJ
    Euro Surveill; 2023 Jan; 28(4):. PubMed ID: 36700868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuraminidase inhibitors for critically ill children with influenza.
    Louie JK; Yang S; Samuel MC; Uyeki TM; Schechter R
    Pediatrics; 2013 Dec; 132(6):e1539-45. PubMed ID: 24276847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients.
    Lee N; Leo YS; Cao B; Chan PK; Kyaw WM; Uyeki TM; Tam WW; Cheung CS; Yung IM; Li H; Gu L; Liu Y; Liu Z; Qu J; Hui DS
    Eur Respir J; 2015 Jun; 45(6):1642-52. PubMed ID: 25573405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
    Muthuri SG; Venkatesan S; Myles PR; Leonardi-Bee J; Al Khuwaitir TS; Al Mamun A; Anovadiya AP; Azziz-Baumgartner E; Báez C; Bassetti M; Beovic B; Bertisch B; Bonmarin I; Booy R; Borja-Aburto VH; Burgmann H; Cao B; Carratala J; Denholm JT; Dominguez SR; Duarte PA; Dubnov-Raz G; Echavarria M; Fanella S; Gao Z; Gérardin P; Giannella M; Gubbels S; Herberg J; Iglesias AL; Hoger PH; Hu X; Islam QT; Jiménez MF; Kandeel A; Keijzers G; Khalili H; Knight M; Kudo K; Kusznierz G; Kuzman I; Kwan AM; Amine IL; Langenegger E; Lankarani KB; Leo YS; Linko R; Liu P; Madanat F; Mayo-Montero E; McGeer A; Memish Z; Metan G; Mickiene A; Mikić D; Mohn KG; Moradi A; Nymadawa P; Oliva ME; Ozkan M; Parekh D; Paul M; Polack FP; Rath BA; Rodríguez AH; Sarrouf EB; Seale AC; Sertogullarindan B; Siqueira MM; Skręt-Magierło J; Stephan F; Talarek E; Tang JW; To KK; Torres A; Törün SH; Tran D; Uyeki TM; Van Zwol A; Vaudry W; Vidmar T; Yokota RT; Zarogoulidis P; ; Nguyen-Van-Tam JS
    Lancet Respir Med; 2014 May; 2(5):395-404. PubMed ID: 24815805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuraminidase inhibitors for preventing and treating influenza in children.
    Wang K; Shun-Shin M; Gill P; Perera R; Harnden A
    Cochrane Database Syst Rev; 2012 Jan; 1():CD002744. PubMed ID: 22258949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuraminidase inhibitor resistance in influenza viruses.
    Reece PA
    J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Clinical Courses of Patients with Influenza after Neuraminidase Inhibitors Treatment: A Postcard Survey of the 2013-2014 Influenza Season in Osaka.
    Yoshi N; Tocino Y; Fujioka M; Kureya Y; Asai K; Kimura T; Shinataku H; Hirata K
    Osaka City Med J; 2016 Dec; 62(2):29-38. PubMed ID: 30550708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
    Meijer A; Rebelo-de-Andrade H; Correia V; Besselaar T; Drager-Dayal R; Fry A; Gregory V; Gubareva L; Kageyama T; Lackenby A; Lo J; Odagiri T; Pereyaslov D; Siqueira MM; Takashita E; Tashiro M; Wang D; Wong S; Zhang W; Daniels RS; Hurt AC
    Antiviral Res; 2014 Oct; 110():31-41. PubMed ID: 25043638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013.
    Takemoto Y; Asai T; Ikezoe I; Yano T; Ichikawa M; Miyagawa S; Matsumoto J
    Chemotherapy; 2013; 59(5):373-8. PubMed ID: 24821568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.
    Monto AS; McKimm-Breschkin JL; Macken C; Hampson AW; Hay A; Klimov A; Tashiro M; Webster RG; Aymard M; Hayden FG; Zambon M
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2395-402. PubMed ID: 16801417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
    Jefferson T; Jones MA; Doshi P; Del Mar CB; Heneghan CJ; Hama R; Thompson MJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD008965. PubMed ID: 22258996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Oseltamivir After Hospital Admission Is Associated With Shortened Hospitalization: A 5-Year Analysis of Oseltamivir Timing and Clinical Outcomes.
    Katzen J; Kohn R; Houk JL; Ison MG
    Clin Infect Dis; 2019 Jun; 69(1):52-58. PubMed ID: 30304487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of antiviral treatment in preventing death in severe hospitalised influenza cases over six seasons.
    Domínguez A; Romero-Tamarit A; Soldevila N; Godoy P; Jané M; Martínez A; Torner N; Caylà JA; Rius C;
    Epidemiol Infect; 2018 May; 146(7):799-808. PubMed ID: 29606178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study.
    Chen L; Han X; Li YL; Zhang C; Xing X
    BMC Infect Dis; 2020 Aug; 20(1):628. PubMed ID: 32842994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.
    Kumar D; Ison MG; Mira JP; Welte T; Hwan Ha J; Hui DS; Zhong N; Saito T; Katugampola L; Collinson N; Williams S; Wildum S; Ackrill A; Clinch B; Lee N
    Lancet Infect Dis; 2022 May; 22(5):718-730. PubMed ID: 35085510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.
    Heneghan CJ; Onakpoya I; Jones MA; Doshi P; Del Mar CB; Hama R; Thompson MJ; Spencer EA; Mahtani KR; Nunan D; Howick J; Jefferson T
    Health Technol Assess; 2016 May; 20(42):1-242. PubMed ID: 27246259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.
    Ishiguro N; Koseki N; Kaiho M; Ariga T; Kikuta H; Oba K; Togashi T; Morita K; Inagawa A; Okamura A; Yamazaki S; Shida S; Konno M; Kawamura N; Ishizaka A; Takada K; Tsubakihara K; Nagano N; Shibata M; Furuyama H; Matsuzono Y; Koike A; Murashita M; Hatae Y; Arioka H; Yamanaka T; Watanabe T; Tabata Y; Kumita Y; Hazama K; Akutsu Y; Aoyagi H; Tobise C; Azuma K; Yasoshima K; Sawada Y; Uetsuji K; Tsuchida A; Tsuchiyama A; Yasuda K; Odagawa Y; Yoshioka M
    J Infect Chemother; 2018 Jun; 24(6):449-457. PubMed ID: 29487035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors.
    Brown SK; Tseng YY; Aziz A; Baz M; Barr IG
    Antiviral Res; 2022 Apr; 200():105280. PubMed ID: 35304163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.
    Kawai N; Ikematsu H; Kawashima T; Maeda T; Ukai H; Hirotsu N; Iwaki N; Kashiwagi S
    Influenza Other Respir Viruses; 2013 May; 7(3):448-55. PubMed ID: 22897904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.